LFG
CYTK icon

Larson Financial Group’s Cytokinetics CYTK Stock Holding History

Larson Financial Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
1,814
+8
+0.4% +$574 ﹤0.01% 957
2026
Q1 		$119K Sell
1,806
-27
-1% -$1.72K ﹤0.01% 920
2025
Q4 		$116K Sell
1,833
-19
-1% -$1.18K ﹤0.01% 877
2025
Q3 		$102K Buy
1,852
+1,488
+409% +$61.3K ﹤0.01% 895
2025
Q2 		$12K Buy
364
+297
+443% +$10.3K ﹤0.01% 1717
2025
Q1 		$2.69K Buy
67
+64
+2,133% +$2.94K ﹤0.01% 2074
2024
Q4 		$141 Buy
+3
New +$156 ﹤0.01% 2540
2023
Q4 		– Sell
-300
Closed -$8.84K – 1822
2023
Q3 		$8.84K Buy
300
+154
+105% +$5.13K ﹤0.01% 1033
2023
Q2 		$4.76K Hold
146
– – ﹤0.01% 1116
2023
Q1 		$5.14K Buy
+146
New +$5.96K ﹤0.01% 1078

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's CYTK Position: Q2 2026 in Review

Larson Financial Group increased its Cytokinetics (CYTK) stake by 0.44% in Q2 2026, buying an estimated $574 and bringing the position to 1,814 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #957.

Larson Financial Group first reported a position in CYTK in Q1 2023 and has held it in 10 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Larson Financial Group held 1,814 shares of Cytokinetics worth $155K as of Q2 2026.
  • Larson Financial Group bought 8 Cytokinetics shares in Q2 2026, an estimated $574.
  • Cytokinetics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #957 holding.
  • Larson Financial Group first reported a position in Cytokinetics in Q1 2023 and has held it in 10 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.